Top Markets
#1 Black Phoenix Black Phoenix +829.97%
#2 pipedog pipedog +41.42%
#3 PondCoin PondCoin +34.34%
#4 Bless Bless +32.22%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +28.74%
#6 SAFEcoin SAFEcoin +26.51%
#7 Beam Beam +24.69%
#8 Magma Finance Magma Finance +19.36%
#9 Seeker Seeker +19.26%
#10 YFSX YFSX +16.15%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Taysha Gene Therapies, Inc. Taysha Gene Therapies, Inc.

Taysha Gene Therapies, Inc.

TSHA
Rank in Stocks #6654
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and... Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
Share Price
$6.02
Market Cap
$1.93B
Change (1 day)
0.00%
Change (1 year)
102.69%
Country
US
Trade Taysha Gene Therapies, Inc. (TSHA)

Category

Healthcare
Revenue for Taysha Gene Therapies, Inc. (TSHA)
Revenue in Aug 2026 TTM: 0
According to Taysha Gene Therapies, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Taysha Gene Therapies, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH